Doxorubicin-loaded nanoparticles for patients with advanced hepatocellular carcinoma after sorafenib treatment failure (RELIVE): a phase 3 randomised controlled trialPhilippe Merle, Gabriele Luppi, Jean–Pierre Bronowicki et al.|The Lancet. Gastroenterology & hepatology|2019Cited by 61
P1111 ANRS HC15 NRFI: LONG-TERM MAINTENANCE THERAPY WITH A COMBINATION OF RIBAVIRIN AND PEGYLATED INTERFERON IN CHRONIC HEPATITIS C. RESULTS OF A MULTICENTER RANDOMIZED CONTROLLED TRIALD. Guyader, Jean Delwaide, Éric Bellissant et al.|Journal of Hepatology|2014Cited by 0